Developer docs
API playgroundTry for free, no card

Search company profiles

Cellevate

Full company profile

uuid000265c

Namestring
Cellevate
Legal namestring
Cellevate AB
Websiteurl
cellevate.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Cellevate AB is a Swedish biotech company founded in 2014 as a spin-out from NanoLund at Lund University, headquartered at Medicon Village in Lund, Sweden. The company develops and commercializes next-generation cell culture products for upstream bioprocessing, built on its proprietary Cellevat3d® nanofiber technology platform. The core technology uses post-electrospinning fabrication to produce cellulose-based monofibers and 3D cross-linked fiber structures that provide up to 60 times larger surface area than conventional bead-based microcarriers, enabling high cell-density 3D spheroid cultures in standard stirred-tank bioreactors.

The commercial product portfolio comprises two launched products: Cellevat3d® nanofiber microcarriers for viral vector production (AAV, lentivirus) — launched globally at BIO-Europe 2024 — and Cellevat3d® VAX nanofiber microcarriers specifically optimized for Vero cell-based viral vaccine production, launched at the World Vaccine Congress Europe in October 2025. Two pipeline products extend the platform: iPSC nanofiber microcarriers (expected 2027 launch, supported by a EUR 1M Eurostar grant consortium with Fraunhofer IBMT and OLS) and nanofiber macrocarriers for MSC and cell therapy applications in packed- and fixed-bed bioreactors. Validated performance includes 3-13.5-fold higher viral titers, up to 85% production cost reductions, and 70% cost reductions per gene therapy dose across multiple independent studies.

Cellevate sells directly to biopharmaceutical companies, CDMOs, and academic research institutions via an enterprise field-sales motion, with a dedicated US sales and support team established in 2024-2025. Products are manufactured at the company's ISO 9001:2015-certified, GMP-compliant cleanroom facility in Lund, with quote-based bulk pricing (€1,500 for a 0.2g starter pack, commercial volumes quoted). The company is venture capital-backed (Industrifonden, EIC Fund, Onsight Ventures, Almi Invest) with approximately €6.6M in total equity funding plus €3.48M in non-dilutive grants as of early 2026. The leadership team and board include senior bioprocessing veterans from Cytiva, Sartorius, Lonza, AstraZeneca, and GE Healthcare.

Short descriptiontext

Cellevate AB is a Swedish biotech company developing and commercializing proprietary cellulose-based nanofiber microcarriers (Cellevat3d®) for upstream bioprocessing, sold directly to biopharmaceutical companies and CDMOs for viral vector, viral vaccine, and cell therapy manufacturing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanofiber microcarriers, viral vector production, cell culture systems, upstream bioprocessing, biopharmaceutical consumables
Industry3 codes
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Nanotechnology541713
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Plastic Material, Synth Resin/Rubber, Cellulos (No Glass)2820
Product category
Bioprocessing Consumables
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Nanofiber Microcarrier Products
TypeHardware Sales
Description

Sale of Cellevat3d® nanofiber microcarriers for viral vector, viral vaccine, and cell therapy biomanufacturing. Products available for ordering include Starter Pack (€1500 for 0.2g) and bulk quantities (500g). Revenue generated through direct product sales to biopharmaceutical companies and CDMOs.

cellevate.com
2Pipeline Products
TypeHardware Sales
Description

Future revenue expected from iPSC nanofiber microcarriers (launch 2027) and nanofiber macrocarriers for cell therapy applications.

cellevate.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Cellevat3d® Nanofiber Microcarriers Starter Pack
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€1500 for 0.2g starter pack. Bulk quantities available (e.g., 500g). Quote-based pricing for larger commercial volumes.

cellevate.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Cellevat3d
Description

Proprietary nanofiber technology platform for cell culture products enabling industrial-scale production of nanofiber-based cell culture systems for biomanufacturing.

cellevate.com
+3 more records
Core offering1 text field

Cellevate develops and sells cellulose-based nanofiber microcarriers under the Cellevat3d® brand for upstream bioprocessing of viral vectors (AAV, lentivirus) and viral vaccines. Products are manufactured at a GMP-compliant cleanroom in Lund and sold in starter packs (0.2 g) and bulk (500 g) quantities directly to biopharmaceutical companies and CDMOs. The platform addresses yield, cost, and scalability challenges in cell and gene therapy and vaccine manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 13.5-fold higher infectious EV71 vaccine titers (1.60×10⁶ TCID50/mL vs 1.19×10⁵ TCID50/mL)
+9 more records
Product overview1 text field

Cellevate offers a platform-based product portfolio centered on its proprietary Cellevat3d® nanofiber technology for upstream bioprocessing. The platform consists of two commercialized products: Cellevat3d® nanofiber microcarriers (for viral vector production including AAV and lentivirus) and Cellevat3d® VAX nanofiber microcarriers (for viral vaccine production). Two pipeline products extend the platform: iPSC nanofiber microcarriers (expected 2027 launch for stem cell therapy applications) and nanofiber macrocarriers (for cell therapy using mesenchymal stem cells). All products are based on cellulose-derived nanofibers that provide up to 60x larger surface area compared to conventional bead-based microcarriers, enabling 3D spheroid formation, higher cell densities, and significantly improved viral titers. Products are scalable from R&D to commercial production in stirred tank bioreactors and are designed for single-use bioprocessing workflows.

Product and service4 records
1Cellevat3d® nanofiber microcarriers Starter Pack
CategoryNanofiber microcarriers / Upstream bioprocessing consumables
Description

A novel category of nanofiber-based cell culture microcarriers for viral vector production (AAV, lentivirus) in stirred-tank bioreactors. Cellulose-based nanofibers with average 500 nm diameter, 75 µm length, and cationic surface charge provide up to 60x larger surface area (53,000 cm²/g) than bead-based microcarriers, enabling homogeneous 3D spheroid formation, high cell viability (94–99%), and 3–5-fold higher viral vector titers. Sold to biopharmaceutical developers and CDMOs for gene therapy manufacturing.

2Cellevat3d® VAX nanofiber microcarriers
CategoryNanofiber microcarriers / Vaccine bioprocessing consumables
Description

Nanofiber microcarriers specifically optimized for viral vaccine production using adherent cell lines such as Vero cells in stirred-tank bioreactors. Promotes homogeneous 3D spheroid cultures with >13-fold higher viral vaccine titers versus industry-standard microcarriers and >90% transfection efficiency. Animal-component-free and manufactured under GMP-compliant, ISO 9001:2015 certified, 21 CFR 820 quality system. Targeted at vaccine manufacturers including emerging applications such as oncolytic cancer vaccines.

3Cellevat3d® iPSC nanofiber microcarriers
CategoryNanofiber microcarriers / Stem cell bioprocessing (pipeline)
Description

Pipeline nanofiber microcarriers designed for large-scale production of induced pluripotent stem cells (iPSCs) for regenerative medicine and cell therapy applications. Built on the same post-electrospinning cellulose nanofiber platform used in commercial products, scaled for iPSC expansion. Currently in development with expected commercial launch in 2027.

4Cellevat3d® nanofiber macrocarriers
CategoryNanofiber macrocarriers / Cell therapy bioprocessing (pipeline)
Description

Pipeline product consisting of cross-linked nanofiber-based cellulose macrocarriers designed for cell therapy applications in packed- and fixed-bed bioreactors. Specifically targeted at human mesenchymal stem cell (hMSC) production and other adherent cell therapy manufacturing processes. Demonstrated 19-fold increase in cell density with retained high cell viability in development studies.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierImportantTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Strategic collaboration agreement integrating InVitria's high-performance, chemically defined, animal-component-free cell culture media with Cellevate's Cellevat3d® nanofiber microcarrier platform. Joint development program includes microcarrier screening, process optimization, virus production studies, and scale-up activities aimed at generating performance data to support future commercial deployment in viral vaccine manufacturing.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-08-19
Description

CDMO conducted benchmarking study demonstrating 11.4-fold higher infectious enterovirus titers and 17-fold increase in cell-specific virus yield using Cellevat3d® nanofiber microcarriers vs industry-standard microcarriers.

3Fraunhofer IBMT
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-25
Description

Eurostar consortium partner providing expertise in applied stem cell research and biomedical engineering. Three-year project validating Cellevat3d® nanofiber microcarriers for large-scale iPSC production in OLS bioreactor, including benchmarking data vs market standard processes.

cellevate.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-25
Description

German bioreactor company and Eurostar consortium partner providing specialized knowhow in cutting-edge bioreactor technologies and cell culture systems for large-scale iPSC production validation.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-25
Description

Academic collaborator conducting AAV9 benchmarking studies demonstrating 3.1-fold significant increase in vector titer. Dr. John Counsell (Associate Professor in Medical Innovation) presenting validation results.

Strategic tierImportantTypeStrategic or Co-development PartnerAnnounced on2023-06-20
Description

Collaboration for research in viral vaccine production with Dr. Yvonne Genzel's upstream processing team at Max Planck Institute in Magdeburg, Germany.

7Dr. Yvonne Genzel (Max Planck Institute)
Strategic tierImportantTypeTechnology or IntegrationAnnounced on2023-05-29
Description

Scientific Advisory Board member, globally recognized expert in vaccine bioprocess engineering, particularly animal cell culture and virus production in bioreactor systems. Contributed to vaccine production validation program.

cellevate.com
8Dr. Thierry Ziegler
Strategic tierImportantTypeTechnology or IntegrationAnnounced on2023-05-04
Description

Scientific Advisory Board member with 25+ years expertise in biopharmaceutical development and production (Merck-Serono, Igyxos, Sanofi, Cellectis). Provides expertise in CAR-T, CMC, and regulatory aspects of biologics.

cellevate.com
Strategic tierImportantTypeTechnology or IntegrationAnnounced on2023-04-26
Description

Vinnova-funded collaborative study demonstrating positive feasibility results for AAV vector transfection and production using Cellevat3d™ microcarriers.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-03-29
Description

Expanded collaboration for cell culture experiments optimizing use of Cellevat3d™ microcarriers in AAV-based production for cell and gene therapy. Dr. Jean-Christophe Bourdon's team conducting validation studies since 2021, generating benchmarking data for commercial launch.

11AdBIOPRO Consortium
Strategic tierImportantTypeStrategic or Co-development PartnerAnnounced on2023-03-22
Description

Competence Centre for Advanced BioProduction at KTH with 24 member organizations including AstraZeneca, Cytiva, BioInvent, and others. Cellevate is technology provider for upstream AAV, lentivirus, and cell therapy bioproduction.

cellevate.com
Strategic tierImportantTypeTechnology or IntegrationAnnounced on2022-12-20
Description

Vinnova/STUNS Life Science funded validation study at Testa Center in Uppsala, Sweden, demonstrating successful scale-up of Cellevat3d® nanofiber microcarriers in 10L Xcellerex XDR single-use stirred tank bioreactor.

13Dr. Véronique Chotteau (KTH)
Strategic tierImportantTypeTechnology or IntegrationAnnounced on2022-11-22
Description

Scientific Advisory Board member and Principal Investigator of Cell Technology group at KTH. Director of AdBIOPRO consortium, world-leading expert in mammalian cell culture and continuous bioprocessing.

cellevate.com
Strategic tierSupportingTypeOthersAnnounced on2022-11-09
Description

SmiLe alumni member using their newly upgraded laboratories equipped for gene therapy applications at Medicon Village in Lund.

Strategic tierImportantTypeTechnology or IntegrationAnnounced on2022-02-01
Description

Vinnova-funded collaboration (5.25 MSEK grant) for development of more effective production of extracellular vesicles from hematopoietic and mesenchymal stem cells using Cellevat3d® nanofiber technology.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global bioprocessing leader (formerly GE Healthcare Life Sciences) selling Cytodex microcarriers, bioreactors and upstream consumables. Direct competitor in microcarriers for viral vector and vaccine production, and broader portfolio incumbent across cell and gene therapy bioprocessing.

TypeBroad incumbent
Description

Major bioprocessing supplier with CultiSpher-S and other microcarriers plus single-use bioreactors. Competes head-to-head with Cellevat3d® in upstream microcarriers for cell and gene therapy applications.

TypeBroad incumbent
Description

Diversified life sciences giant offering microcarriers (e.g., Gibco) and complete upstream bioprocessing workflows. A broad incumbent in the same customer workflows as Cellevate for viral vector and vaccine manufacturing.

4Corning Life Sciences
TypeBroad incumbent
Description

Supplies Corning® microcarriers and cell culture vessels widely used in bioprocessing. Competes with Cellevate in adherent cell culture substrates for vaccine and cell therapy production.

TypeBroad incumbent
Description

Manufacturer of bioreactors and bioprocessing equipment serving similar upstream cell culture customers. Adjacent competitor in the upstream bioprocessing ecosystem where Cellevate's microcarriers are deployed.

TypeDirect peer
Description

Specialist in single-use bioreactors and cell culture systems for cell and gene therapy manufacturing. Direct peer in the upstream bioprocessing tooling stack where Cellevate's nanofiber microcarriers are used.

TypeDirect peer
Description

Supplies cell culture media and bioprocessing solutions for cell and gene therapy, regenerative medicine and vaccine manufacturing. Comparable as a supplier of upstream cell culture inputs alongside Cellevate's microcarriers.

TypeEmerging player
Description

Emerging supplier of MSC and cell therapy enabling products (media, cells, bioprocess media). Relevant comparable in the cell therapy upstream workflow that Cellevate's macrocarriers pipeline targets.

TypeEmerging player
Description

Supplies cell culture media, substrates and reagents for stem cell and cell therapy workflows. Comparable emerging player in iPSC and stem cell culture consumables, adjacent to Cellevate's iPSC microcarrier pipeline.

TypeEmerging player
Description

Develops 3D cell culture technologies including hydrogels and scaffolds for cell expansion. Comparable emerging player in 3D and scaffold-based cell culture substrates for advanced cell therapy applications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellevate

Bioprocessing Consumablescellevate.com

Cellevate AB is a Swedish biotech company developing and commercializing proprietary cellulose-based nanofiber microcarriers (Cellevat3d®) for upstream bioprocessing, sold directly to biopharmaceutical companies and CDMOs for viral vector, viral vaccine, and cell therapy manufacturing.

What Cellevate does

Cellevate AB is a Swedish biotech company founded in 2014 as a spin-out from NanoLund at Lund University, headquartered at Medicon Village in Lund, Sweden. The company develops and commercializes next-generation cell culture products for upstream bioprocessing, built on its proprietary Cellevat3d® nanofiber technology platform. The core technology uses post-electrospinning fabrication to produce cellulose-based monofibers and 3D cross-linked fiber structures that provide up to 60 times larger surface area than conventional bead-based microcarriers, enabling high cell-density 3D spheroid cultures in standard stirred-tank bioreactors.

The commercial product portfolio comprises two launched products: Cellevat3d® nanofiber microcarriers for viral vector production (AAV, lentivirus) — launched globally at BIO-Europe 2024 — and Cellevat3d® VAX nanofiber microcarriers specifically optimized for Vero cell-based viral vaccine production, launched at the World Vaccine Congress Europe in October 2025. Two pipeline products extend the platform: iPSC nanofiber microcarriers (expected 2027 launch, supported by a EUR 1M Eurostar grant consortium with Fraunhofer IBMT and OLS) and nanofiber macrocarriers for MSC and cell therapy applications in packed- and fixed-bed bioreactors. Validated performance includes 3-13.5-fold higher viral titers, up to 85% production cost reductions, and 70% cost reductions per gene therapy dose across multiple independent studies.

Cellevate sells directly to biopharmaceutical companies, CDMOs, and academic research institutions via an enterprise field-sales motion, with a dedicated US sales and support team established in 2024-2025. Products are manufactured at the company's ISO 9001:2015-certified, GMP-compliant cleanroom facility in Lund, with quote-based bulk pricing (€1,500 for a 0.2g starter pack, commercial volumes quoted). The company is venture capital-backed (Industrifonden, EIC Fund, Onsight Ventures, Almi Invest) with approximately €6.6M in total equity funding plus €3.48M in non-dilutive grants as of early 2026. The leadership team and board include senior bioprocessing veterans from Cytiva, Sartorius, Lonza, AstraZeneca, and GE Healthcare.

Cellevate firmographics

Firmographics
Name
Cellevate
Legal name
Cellevate AB
Website
https://cellevate.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Cellevate AB is a Swedish biotech company developing and commercializing proprietary cellulose-based nanofiber microcarriers (Cellevat3d®) for upstream bioprocessing, sold directly to biopharmaceutical companies and CDMOs for viral vector, viral vaccine, and cell therapy manufacturing.
Ownership category
akta.pro rank

Cellevate industry classification

Industry
Product category
Bioprocessing Consumables
NAICS
Research and Development in Nanotechnology (541713), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820)
akta.pro industry
PRIMARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Nanofiber microcarriers
  • Viral vector production
  • Cell culture systems
  • Upstream bioprocessing
  • Biopharmaceutical consumables

Where Cellevate is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Cellevate business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Nanofiber Microcarrier Products: Sale of Cellevat3d® nanofiber microcarriers for viral vector, viral vaccine, and cell therapy biomanufacturing. Products available for ordering include Starter Pack (€1500 for 0.2g) and bulk quantities (500g). Revenue generated through direct product sales to biopharmaceutical companies and CDMOs.
  2. Pipeline Products: Future revenue expected from iPSC nanofiber microcarriers (launch 2027) and nanofiber macrocarriers for cell therapy applications.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCellevat3d® Nanofiber Microcarriers Starter Pack

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Cellevate product offering

Product offering

Core offering

Cellevate develops and sells cellulose-based nanofiber microcarriers under the Cellevat3d® brand for upstream bioprocessing of viral vectors (AAV, lentivirus) and viral vaccines. Products are manufactured at a GMP-compliant cleanroom in Lund and sold in starter packs (0.2 g) and bulk (500 g) quantities directly to biopharmaceutical companies and CDMOs. The platform addresses yield, cost, and scalability challenges in cell and gene therapy and vaccine manufacturing.

Product overview

Cellevate offers a platform-based product portfolio centered on its proprietary Cellevat3d® nanofiber technology for upstream bioprocessing. The platform consists of two commercialized products: Cellevat3d® nanofiber microcarriers (for viral vector production including AAV and lentivirus) and Cellevat3d® VAX nanofiber microcarriers (for viral vaccine production). Two pipeline products extend the platform: iPSC nanofiber microcarriers (expected 2027 launch for stem cell therapy applications) and nanofiber macrocarriers (for cell therapy using mesenchymal stem cells). All products are based on cellulose-derived nanofibers that provide up to 60x larger surface area compared to conventional bead-based microcarriers, enabling 3D spheroid formation, higher cell densities, and significantly improved viral titers. Products are scalable from R&D to commercial production in stirred tank bioreactors and are designed for single-use bioprocessing workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • Cellevat3d: Proprietary nanofiber technology platform for cell culture products enabling industrial-scale production of nanofiber-based cell culture systems for biomanufacturing.
  • Cellevat3d VAX
  • Cellevat3d iPSC
  • Cellevat3d nanofiber macrocarriers

Products and services

  • Cellevat3d® nanofiber microcarriers Starter Pack A novel category of nanofiber-based cell culture microcarriers for viral vector production (AAV, lentivirus) in stirred-tank bioreactors. Cellulose-based nanofibers with average 500 nm diameter, 75 µm length, and cationic surface charge provide up to 60x larger surface area (53,000 cm²/g) than bead-based microcarriers, enabling homogeneous 3D spheroid formation, high cell viability (94–99%), and 3–5-fold higher viral vector titers. Sold to biopharmaceutical developers and CDMOs for gene therapy manufacturing.
  • Cellevat3d® VAX nanofiber microcarriers Nanofiber microcarriers specifically optimized for viral vaccine production using adherent cell lines such as Vero cells in stirred-tank bioreactors. Promotes homogeneous 3D spheroid cultures with >13-fold higher viral vaccine titers versus industry-standard microcarriers and >90% transfection efficiency. Animal-component-free and manufactured under GMP-compliant, ISO 9001:2015 certified, 21 CFR 820 quality system. Targeted at vaccine manufacturers including emerging applications such as oncolytic cancer vaccines.
  • Cellevat3d® iPSC nanofiber microcarriers Pipeline nanofiber microcarriers designed for large-scale production of induced pluripotent stem cells (iPSCs) for regenerative medicine and cell therapy applications. Built on the same post-electrospinning cellulose nanofiber platform used in commercial products, scaled for iPSC expansion. Currently in development with expected commercial launch in 2027.
  • Cellevat3d® nanofiber macrocarriers Pipeline product consisting of cross-linked nanofiber-based cellulose macrocarriers designed for cell therapy applications in packed- and fixed-bed bioreactors. Specifically targeted at human mesenchymal stem cell (hMSC) production and other adherent cell therapy manufacturing processes. Demonstrated 19-fold increase in cell density with retained high cell viability in development studies.

Quantifiable outcome

  • 13.5-fold higher infectious EV71 vaccine titers (1.60×10⁶ TCID50/mL vs 1.19×10⁵ TCID50/mL)
  • +9 more outcomes

Companies that use Cellevate

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Cellevate technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cellevate partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered important, core, major and supporting.

  • InVitria, Inc.importantStrategic or Co-development Partner · 10 March 2026Strategic collaboration agreement integrating InVitria's high-performance, chemically defined, animal-component-free cell culture media with Cellevate's Cellevat3d® nanofiber microcarrier platform. Joint development program includes microcarrier screening, process optimization, virus production studies, and scale-up activities aimed at generating performance data to support future commercial deployment in viral vaccine manufacturing.
  • IntravacccoreTechnology or Integration · 19 August 2025CDMO conducted benchmarking study demonstrating 11.4-fold higher infectious enterovirus titers and 17-fold increase in cell-specific virus yield using Cellevat3d® nanofiber microcarriers vs industry-standard microcarriers.
  • Fraunhofer IBMTmajorStrategic or Co-development Partner · 25 April 2025Eurostar consortium partner providing expertise in applied stem cell research and biomedical engineering. Three-year project validating Cellevat3d® nanofiber microcarriers for large-scale iPSC production in OLS bioreactor, including benchmarking data vs market standard processes.
  • OLS (Omni Life Science)majorStrategic or Co-development Partner · 25 April 2025German bioreactor company and Eurostar consortium partner providing specialized knowhow in cutting-edge bioreactor technologies and cell culture systems for large-scale iPSC production validation.
  • UCL (University College London)coreTechnology or Integration · 25 October 2024Academic collaborator conducting AAV9 benchmarking studies demonstrating 3.1-fold significant increase in vector titer. Dr. John Counsell (Associate Professor in Medical Innovation) presenting validation results.
  • Max Planck Society (Max Planck Institute for Dynamics of Complex Technical Systems)importantStrategic or Co-development Partner · 20 June 2023Collaboration for research in viral vaccine production with Dr. Yvonne Genzel's upstream processing team at Max Planck Institute in Magdeburg, Germany.
  • Dr. Yvonne Genzel (Max Planck Institute)importantTechnology or Integration · 29 May 2023Scientific Advisory Board member, globally recognized expert in vaccine bioprocess engineering, particularly animal cell culture and virus production in bioreactor systems. Contributed to vaccine production validation program.
  • Dr. Thierry ZieglerimportantTechnology or Integration · 4 May 2023Scientific Advisory Board member with 25+ years expertise in biopharmaceutical development and production (Merck-Serono, Igyxos, Sanofi, Cellectis). Provides expertise in CAR-T, CMC, and regulatory aspects of biologics.
  • RISE Research Institutes of SwedenimportantTechnology or Integration · 26 April 2023Vinnova-funded collaborative study demonstrating positive feasibility results for AAV vector transfection and production using Cellevat3d™ microcarriers.
  • University of DundeecoreTechnology or Integration · 29 March 2023Expanded collaboration for cell culture experiments optimizing use of Cellevat3d™ microcarriers in AAV-based production for cell and gene therapy. Dr. Jean-Christophe Bourdon's team conducting validation studies since 2021, generating benchmarking data for commercial launch.
  • AdBIOPRO ConsortiumimportantStrategic or Co-development Partner · 22 March 2023Competence Centre for Advanced BioProduction at KTH with 24 member organizations including AstraZeneca, Cytiva, BioInvent, and others. Cellevate is technology provider for upstream AAV, lentivirus, and cell therapy bioproduction.
  • Testa CenterimportantTechnology or Integration · 20 December 2022Vinnova/STUNS Life Science funded validation study at Testa Center in Uppsala, Sweden, demonstrating successful scale-up of Cellevat3d® nanofiber microcarriers in 10L Xcellerex XDR single-use stirred tank bioreactor.
  • Dr. Véronique Chotteau (KTH)importantTechnology or Integration · 22 November 2022Scientific Advisory Board member and Principal Investigator of Cell Technology group at KTH. Director of AdBIOPRO consortium, world-leading expert in mammalian cell culture and continuous bioprocessing.
  • SmiLe IncubatorsupportingOthers · 9 November 2022SmiLe alumni member using their newly upgraded laboratories equipped for gene therapy applications at Medicon Village in Lund.
  • Karolinska Institutet and Karolinska University HospitalimportantTechnology or Integration · 1 February 2022Vinnova-funded collaboration (5.25 MSEK grant) for development of more effective production of extracellular vesicles from hematopoietic and mesenchymal stem cells using Cellevat3d® nanofiber technology.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Cellevate competitors and assessment

Company assessment

Broad incumbents

  • Cytiva: Global bioprocessing leader (formerly GE Healthcare Life Sciences) selling Cytodex microcarriers, bioreactors and upstream consumables. Direct competitor in microcarriers for viral vector and vaccine production, and broader portfolio incumbent across cell and gene therapy bioprocessing.
  • Sartorius: Major bioprocessing supplier with CultiSpher-S and other microcarriers plus single-use bioreactors. Competes head-to-head with Cellevat3d® in upstream microcarriers for cell and gene therapy applications.
  • Thermo Fisher Scientific: Diversified life sciences giant offering microcarriers (e.g., Gibco) and complete upstream bioprocessing workflows. A broad incumbent in the same customer workflows as Cellevate for viral vector and vaccine manufacturing.
  • Corning Life Sciences: Supplies Corning® microcarriers and cell culture vessels widely used in bioprocessing. Competes with Cellevate in adherent cell culture substrates for vaccine and cell therapy production.
  • Eppendorf: Manufacturer of bioreactors and bioprocessing equipment serving similar upstream cell culture customers. Adjacent competitor in the upstream bioprocessing ecosystem where Cellevate's microcarriers are deployed.

Direct peers

  • PBS Biotech: Specialist in single-use bioreactors and cell culture systems for cell and gene therapy manufacturing. Direct peer in the upstream bioprocessing tooling stack where Cellevate's nanofiber microcarriers are used.
  • FUJIFILM Irvine Scientific: Supplies cell culture media and bioprocessing solutions for cell and gene therapy, regenerative medicine and vaccine manufacturing. Comparable as a supplier of upstream cell culture inputs alongside Cellevate's microcarriers.

Emerging players

  • RoosterBio: Emerging supplier of MSC and cell therapy enabling products (media, cells, bioprocess media). Relevant comparable in the cell therapy upstream workflow that Cellevate's macrocarriers pipeline targets.
  • Stemcell Technologies: Supplies cell culture media, substrates and reagents for stem cell and cell therapy workflows. Comparable emerging player in iPSC and stem cell culture consumables, adjacent to Cellevate's iPSC microcarrier pipeline.
  • CelVivo: Develops 3D cell culture technologies including hydrogels and scaffolds for cell expansion. Comparable emerging player in 3D and scaffold-based cell culture substrates for advanced cell therapy applications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Cellevate social profiles

Digital presence

Cellevate compliance and trust

Trust signal

Compliance3 records

Cellevate financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellevate leadership team

Management profile

Number of profiles

Profiles8 records

Cellevate funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellevate M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellevate

What does Cellevate do?

Cellevate develops and sells cellulose-based nanofiber microcarriers under the Cellevat3d® brand for upstream bioprocessing of viral vectors (AAV, lentivirus) and viral vaccines. Products are manufactured at a GMP-compliant cleanroom in Lund and sold in starter packs (0.2 g) and bulk (500 g) quantities directly to biopharmaceutical companies and CDMOs. The platform addresses yield, cost, and scalability challenges in cell and gene therapy and vaccine manufacturing.

Is Cellevate a public or private company?

Cellevate is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellevate founded?

Cellevate was founded in 2014. It employs 11 to 50 people.

Where is Cellevate based?

Cellevate is headquartered in Lund, Sweden, in the Europe region.

How does Cellevate make money?

Two revenue lines are on record. Nanofiber Microcarrier Products are the primary driver. The others are pipeline Products.

Who are Cellevate's main competitors?

Broad incumbents on record are Cytiva, Sartorius, Thermo Fisher Scientific, Corning Life Sciences and Eppendorf. Direct peers are PBS Biotech and FUJIFILM Irvine Scientific. Emerging players are RoosterBio, Stemcell Technologies and CelVivo.

Does Cellevate have an API?

No public API is recorded for Cellevate.

What industry is Cellevate in?

Cellevate's product category is Bioprocessing Consumables. Its primary akta.pro industry code is HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables), with a secondary code of HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 541713 and its SIC code is 2820.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupmafiaCellevate Raises €2M to Scale Nanofiber Technology for Biopharma ManufacturingCellevate raised SEK 21.3 million (about €2 million) to scale its nanofiber-based cell culture technology for biopharma manufacturing. The round was led by Almi Invest, with existing backers including Industrifonden and the EIC Fund. The company is now in a commercialization phase, expanding customer adoption and refining its platform.CellevateCellevate secures SEK 21.3 Million financing to advance commercializationCellevate AB closed a financing round in February 2026, raising SEK 21.3 million from existing shareholders and new investors including Almi Invest. The funding supports commercialization and scale-up of Cellevat3d VAX nanofibers with vaccine producers. The company is ISO 9001:2015 certified and has GMP processes.news.cision.comCellevate caps strong 2025 by achieving ISO 9001:2015 certification and implementing GMP production processes in new cleanroomSwedish biotech company Cellevate has achieved ISO 9001:2015 certification combined with GMP processes in its new cleanroom facility in Lund, marking a major milestone toward becoming an industrial bioprocessing supplier. The company simultaneously completed and validated the cleanroom, which is dedicated to producing its commercial Cellevat3d® nanofiber products for biopharmaceutical customers and CDMOs. The cleanroom was designed and installed by UK-based Guardtech Cleanrooms using a modular construction platform, providing scalable manufacturing capacity for growing commercial demand.NordiclifescienceCellevate, Fraunhofer IBMT and OLS consortium awarded EUR 1 millionCellevate, Fraunhofer IBMT, and OLS received a EUR 1 million award for a three-year project to validate Cellevat3d nanofiber microcarriers for large-scale iPSC production in OLS bioreactors. The consortium will benchmark the process against market standards, with Fraunhofer IBMT leading stem cell research and OLS providing bioreactor expertise.news.cision.comCellevate launches Cellevat3d[®] nanofiber-based cell culture systems designed for faster bioprocessing, more efficient scale up and more than three times the viral vector yieldCellevate has commercially launched its Cellevat3d® nanofiber-based cell culture systems, marking the world's first such technology for viral vector production. The system offers up to 60 times larger surface area for cell growth compared to current solutions, enabling more than three times the viral vector yield and faster scale-up in bioreactors. This launch represents a strategic milestone for the company as it begins commercializing its proprietary nanotechnology for the biopharmaceutical industry.CellevateCellevate closes second seed round, raising 3.2 MEUR to enter into global commercializationCellevate closed its second seed round, raising 3.2 million EUR led by Industrifonden and the European Innovation Council Fund (EIC Fund), bringing total equity funding to 6.6 million EUR. The company is preparing for the global commercialization of its Cellevat3d™ nanofiber microcarriers in November 2024 to enhance productivity in gene therapy biomanufacturing. This capital will fund the establishment of a commercial team in North America, production scaling, and marketing efforts.IndustrifondenCellevate raises 39 million SEK in Seed Financing to accelerate their global commercial launchBiotech company Cellevate has secured 39 million SEK in seed financing led by Industrifonden, with participation from the European Innovation Council Fund and Onsight Ventures. The capital will be used to accelerate the global commercial launch of its proprietary nanofiber-based technology, Cellevat3d™, which aims to improve scalability in biomanufacturing.news.cision.comCellevate raises 39 million SEK in Seed Financing to accelerate their global commercial launchCellevate, a Swedish biotech company, raised 39 million SEK in Seed Financing to support the global commercial launch of its groundbreaking nanofiber-based cell culture technology, Cellevat3d™, as announced on October 10, 2023. This funding round, led by Industrifonden along with the EIC Fund and Onsight Ventures, will help accelerate Cellevate's commercialization plans and enhance its manufacturing capabilities. The company aims to address scalability challenges in biomanufacturing and improve access to next-generation therapies worldwide.CellevateCellevate awarded € 2.48 million grant through the European Innovation Council Accelerator competitive programBiopharmaceutical company Cellevate received a €2.48 million grant from the European Innovation Council Accelerator program to accelerate the industrialization of its Cellevat3d™ Microcarriers technology. This funding will support the development and scale-up of nanofiber-based microcarriers designed to enhance the efficiency of biological drug manufacturing, cell and gene therapy production, and novel vaccines.BioSpacePredictive Oncology Inc.’s Wholly Owned Subsidiary, TumorGenesis, Partners with Cellevate ABPredictive Oncology (NASDAQ: POAI) announced on May 20, 2021 that its wholly owned subsidiary TumorGenesis has partnered with Swedish firm Cellevate AB, combining TumorGenesis' media with Cellevate's engineered matrix materials. The companies will initially work on ovarian cancer, growing tissues in a 3D matrix support system. Financial terms were not disclosed.